12:37 AM EDT, 09/03/2026 (MT Newswires) -- Hutchmed (China) (HCM.L) unit Hutchmed Ltd. agreed to grant a GSK (GSK.L) subsidiary global commercialization rights to HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate. Under the exclusive development and license agreement, GSK will hold commercialization rights worldwide, excluding Mainland China, Hong Kong, Macau, and Taiwan, according to a Thursday release. The London-listed biopharmaceutical company will receive $110 million upfront upon closing, subject to completion of antitrust regulatory reviews. It is also eligible for up to $1.30 billion in development, regulatory and commercial milestone payments, as well as royalties on net sales. Hutchmed Ltd. will lead the global phase 1 development program, which is expected to start in the second half of 2026. Meanwhile, GSK will be responsible for all subsequent clinical development and commercialization activities.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.